Glossary of Benefit-Risk Analysis Terms

Data integrity principles for regulatory compliance: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available. These principles ensure that electronic records meet FDA 21 CFR Part 11 and EMA GMP Annex 11 requirements for audit trails and data traceability.

A Bayesian statistical method for signal detection in pharmacovigilance databases. Used by the WHO Uppsala Monitoring Centre (UMC) to identify drug-adverse event associations from spontaneous reporting data. BCPNN calculates an Information Component (IC) that measures the degree to which a drug-event combination is reported more frequently than expected by chance.

The evaluation and quantification of the balance between therapeutic benefits and potential risks of a medicinal product. BRA is a regulatory requirement throughout the product lifecycle (clinical development, marketing authorization, post-marketing surveillance) and forms the foundation for regulatory decision-making by FDA, EMA, and other health authorities.

A structured framework for benefit-risk assessment developed by CDER and endorsed by FDA. The BRAT framework uses value trees to organize benefits and risks, effects tables to quantify outcomes, and a systematic approach to communicate benefit-risk balance to stakeholders. Components include: decision context, benefit and risk outcomes, outcome importance, uncertainty characterization, and benefit-risk summary.

An internationally agreed-upon format for organizing regulatory submission documents (ICH M4). The CTD consists of five modules: Module 1 (regional administrative information), Module 2 (summaries including benefit-risk assessment), Module 3 (quality), Module 4 (nonclinical), and Module 5 (clinical). Module 2.5 contains the Clinical Overview with integrated benefit-risk summary.

A pharmacological or clinical response to co-administration of two or more drugs that is different from the effects of either drug given alone. DDIs can be pharmacokinetic (affecting absorption, distribution, metabolism, or excretion) or pharmacodynamic (affecting drug action at the receptor or physiological system level). Critical for benefit-risk assessment in polypharmacy scenarios.

The regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union. EMA coordinates the EU's scientific resources through a network of national competent authorities and publishes guidance on benefit-risk methodology, pharmacovigilance (GVP modules), and regulatory submission requirements.

A database containing information on adverse event and medication error reports submitted to FDA. FAERS supports post-marketing safety surveillance through spontaneous reporting from healthcare professionals, consumers, and manufacturers. Data is publicly available in quarterly extracts and used for disproportionality analysis and signal detection.

EMA guidelines outlining standards for pharmacovigilance activities in the European Union. GVP consists of 16 modules covering topics including pharmacovigilance systems, signal management, risk management plans, PSURs, and communication. Module V specifically addresses risk management systems and benefit-risk evaluation methodology.

A multidisciplinary process evaluating medical, social, economic, and ethical implications of health technologies. HTA bodies (NICE, G-BA, CADTH, etc.) assess clinical effectiveness, safety, and cost-effectiveness to inform reimbursement and formulary decisions. Regulatory benefit-risk assessments provide foundational evidence for HTA submissions.

An international organization bringing together regulatory authorities and pharmaceutical industry to develop harmonized technical guidelines for drug registration. Key ICH guidelines for benefit-risk include E2C(R2) on PSUR/PBRER, E2E on pharmacovigilance planning, and M4E on CTD clinical overview with benefit-risk summary.

A quantitative approach to benefit-risk assessment that explicitly considers multiple criteria (efficacy endpoints, safety outcomes) and their relative importance. MCDA methods include swing weighting, SMAA (Stochastic Multicriteria Acceptability Analysis), and discrete choice experiments. Recommended by EMA and IMI-PROTECT for structured benefit-risk evaluation.

The standardized medical terminology developed under ICH for regulatory communication and pharmacovigilance data exchange. MedDRA uses a five-level hierarchy: System Organ Class (SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred Term (PT), and Lowest Level Term (LLT). Essential for consistent adverse event coding across spontaneous reports, clinical trials, and regulatory submissions.

A data mining algorithm used by FDA for signal detection in FAERS. MGPS uses Bayesian modeling to identify drug-adverse event combinations with unexpectedly high reporting rates. The algorithm produces an Empirical Bayes Geometric Mean (EBGM) score, with EBGM ≥ 2.0 typically indicating a potential signal requiring further investigation.

The ICH-harmonized version of the Periodic Safety Update Report (PSUR) as defined in ICH E2C(R2). PBRERs provide periodic assessments of a medicinal product's benefit-risk balance based on cumulative information during post-approval use. Submitted at defined intervals (typically annually or semi-annually) and must include integrated benefit-risk evaluation sections.

The regulatory authority responsible for ensuring the safety, efficacy, and quality of pharmaceuticals and medical devices in Japan. PMDA reviews marketing authorization applications, conducts post-marketing surveillance, and issues safety guidance. Accepts ICH-formatted submissions including benefit-risk assessments aligned with CTD Module 2.5 requirements.

A disproportionality measure used in pharmacovigilance signal detection. PRR compares the proportion of reports of a specific adverse event for a drug of interest to the proportion of the same event for all other drugs in the database. PRR ≥ 2, chi-square ≥ 4, and ≥ 3 cases is a common threshold for signal generation in spontaneous reporting systems.

A pharmacovigilance document providing an evaluation of the benefit-risk balance of a medicinal product during a defined time period. Now harmonized as PBRER under ICH E2C(R2), but PSUR terminology is still used in some regions. Includes analysis of all available safety data, signal evaluation, and benefit-risk conclusions.

A detailed description of the risk management system for a medicinal product. Required by EMA (GVP Module V) and FDA (REMS for certain products). The RMP includes safety specifications, pharmacovigilance plans, risk minimization measures, and plans for post-authorization efficacy studies (PAES). Must include benefit-risk evaluation in context of proposed risk minimization activities.

An odds ratio measure used in disproportionality analysis for signal detection. ROR compares the odds of a specific adverse event being reported for a drug versus all other drugs. ROR > 1 suggests disproportionate reporting; ROR confidence intervals excluding 1.0 indicate statistical significance. Widely used in pharmacovigilance signal detection algorithms.

Clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD) such as electronic health records, claims databases, registries, and patient-generated data. Increasingly accepted by FDA and EMA to support benefit-risk evaluations, regulatory decisions, and post-marketing surveillance when appropriately designed and validated.